Literature DB >> 25423877

Safety issues and drug-drug interactions with commonly used quinolones.

Antonios Douros1, Katja Grabowski, Ralf Stahlmann.   

Abstract

INTRODUCTION: Quinolones are widely used antimicrobials with good efficacy and favourable safety. Recently, forms of quinolone toxicity such as peripheral neuropathy, retinal detachment or QTc-prolongation have attracted attention. AREAS COVERED: Data on different aspects of direct quinolone toxicity are reviewed and consider risk factors and predisposing structural properties. Indirect forms of quinolone toxicity such as Clostridium difficile infections or adverse reactions associated with drug-drug interactions are also discussed. Finally, the role of transporters in the pharmacokinetics of these antimicrobials and their utilisation in critically ill patients are illustrated. A MEDLINE PubMed search for articles published in English from January 1960 to June 2014 was completed using the terms: quinolone, quinolone-induced toxicity, quinolone pharmacokinetics, quinolone and critically ill, drug-drug interactions. EXPERT OPINION: Quinolones exhibit an important component of the antibiotic arsenal. Although several adverse events have been associated with their use, taking into consideration risk factors, contraindications and potential drug-drug interactions can drastically reduce the respective risks.

Entities:  

Keywords:  drug–drug interactions; quinolones; safety; toxicity

Mesh:

Substances:

Year:  2014        PMID: 25423877     DOI: 10.1517/17425255.2014.970166

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  14 in total

1.  Multi-templates surface molecularly imprinted polymer for rapid separation and analysis of quinolones in water.

Authors:  Yinming Fan; Guolong Zeng; Xiaoguo Ma
Journal:  Environ Sci Pollut Res Int       Date:  2019-12-27       Impact factor: 4.223

2.  The Effects of Levofloxacin on Testis Tissue and Spermatogenesis in Rat.

Authors:  Ramesh Ahmadi; Mehdi Ahmadifar; Elham Safarpour; Nazila Vahidi-Eyrisofla; Mehraneh Darab; Ali Mohammad Eini; AliReza Alizadeh
Journal:  Cell J       Date:  2016-04-04       Impact factor: 2.479

3.  Antimicrobial Use in Patients on a Comfort Care Protocol: A Retrospective Cohort Study.

Authors:  Susan E Merel; Cynthia A Meier; Christy M McKinney; Paul S Pottinger
Journal:  J Palliat Med       Date:  2016-06-16       Impact factor: 2.947

4.  Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease.

Authors:  Masayoshi Sato; Kazuyuki Fujii; Hiroko Takagi; Isao Shibuya; Daisuke Oka; Naomitsu Yamaya; Hiraku Hagita; Makoto Matsumoto; Katsuya Inagaki
Journal:  Dig Dis Sci       Date:  2021-08-31       Impact factor: 3.487

Review 5.  Epididymo-orchitis caused by enteric organisms in men > 35 years old: beyond fluoroquinolones.

Authors:  Laura Ryan; Padraig Daly; Ivor Cullen; Maeve Doyle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-15       Impact factor: 3.267

6.  Editorial Comment.

Authors:  Gregory B Auffenberg; Khurshid R Ghani
Journal:  Urology       Date:  2016-04       Impact factor: 2.649

7.  Moxifloxacin-induced acute psychosis: A case report with literature review.

Authors:  Faizan Mazhar; Shahzad Akram; Nafis Haider
Journal:  J Res Pharm Pract       Date:  2016 Oct-Dec

8.  Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Matteo Bassetti; David Hooper; Glenn Tillotson
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

9.  Administration of oral fluoroquinolone and the risk of rhegmatogenous retinal detachment: A nationwide population-based study in Korea.

Authors:  Seung Yong Choi; Hyun-A Lim; Hyeon Woo Yim; Young-Hoon Park
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

Review 10.  [Three keys to the appropriate choice of oral antibiotic treatment in the respiratory tract infections].

Authors:  R Menéndez; R Cantón; A García-Caballero; J Barberán
Journal:  Rev Esp Quimioter       Date:  2019-12-04       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.